Genetrix, Sygnis Pharma deal

Sygnis shareholders approved the company's acquisition of Genetrix's X-Pol Biotech S.L. subsidiary. X-Pol will become a wholly-owned subsidiary of Sygnis, which will develop and market X-Pol's DNA sequencing technologies and products. Existing X-Pol shareholders will hold 77.5% of Sygnis' shares following the deal. The companies, which said the merger is expected to generate revenues as early as next year, could not be reached for details. The companies signed a binding term sheet earlier this year (see BioCentury, July 23). ...